← ANALYST RATINGS · TIPRANKS
Phathom Pharmaceuticals (PHAT): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $22.20, the highest $26.00, the lowest $20.00. The average is +220.8% from the last price of $6.92.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 | Hold | +8.4% | Reiterated | 30.09.26on TipRanks 08:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 | Hold | +8.4% | Reiterated | 30.09.26on TipRanks 08:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.50 | Hold | +8.4% | Reiterated | 30.09.26on TipRanks 08:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.00 → $7.50+7.1% | Hold | +8.4% | Reiterated | 30.09.26on TipRanks 08:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 | Buy | +15.6% | Upgrade | 30.09.26on TipRanks 08:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 | Hold | +8.4% | Reiterated | 30.09.26on TipRanks 08:05 | — | |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $26.00 | Buy | +275.7% | Reiterated | 21.09.26on TipRanks 13:55 | −2.0%next day +4.2% · 5 days −0.3% | ↗ |
| Daniel Clark★★★★★★★★★★#3492 · hits 65% · avg +17.4% | Leerink Partners | $10.00 | Hold | +44.5% | Initiated | 09.09.26on TipRanks 08:20 | −7.6%next day −2.9% · 5 days −10.2% | ↗ |
| Jenna Davidner★★★★★★★★★★#10265 · hits 25% · avg −5.3% | Barclays | $14.00 | Buy | +102.3% | Reiterated | 17.08.26on TipRanks 04:55 | −2.7%next day +0.4% · 5 days −5.5% | ↗ |
| Chase Knickerbocker★★★★★★★★★★#75 · hits 59% · avg +36.2% | Craig-Hallum | $22.00 → $20.00−9.1% | Buy | +189.0% | Assigned | 31.07.26on TipRanks 09:35 | −3.8%next day +1.2% · 5 days −5.8% | ↗ |
| Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% | Raymond James | $21.00 | Buy | +203.5% | Reiterated | 31.07.26on TipRanks 09:00 | −3.8%next day +1.2% · 5 days −5.8% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $25.00 → $22.00−12.0% | Buy | +217.9% | Reiterated | 31.07.26on TipRanks 07:18 | −3.8%next day +1.2% · 5 days −5.8% | ↗ |
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | $28.00 → $22.00−21.4% | Buy | +217.9% | Reiterated | 30.07.26on TipRanks 14:10 | −24.1%next day −3.8% · 5 days −10.7% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | — | Hold | — | Reiterated | 30.04.26on TipRanks 17:30 | +7.0%next day +7.5% · 5 days −1.1% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | $28.00 | Buy | +304.6% | Reiterated | 15.01.26on TipRanks 06:50 | −1.3%next day −6.1% · 5 days −9.4% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $29.00 | Buy | +319.1% | Reiterated | 13.01.26on TipRanks Jan 14 08:30 | +8.2%next day −2.6% · 5 days −11.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Phathom Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $19.29 at a price of $7.30 (+164.2%); now: $19.29 at $6.92 (+178.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 8 | 12 | 9 | 8 | 1 |
| Buy | 1 | 2 | 2 | 2 | 1 | 0 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.11 (from $-0.25 to $0.06). Last quarter: $-0.21.
Sales
Next quarter’s sales estimate — $85M (from $82M to $88M). Last quarter: $74M.
Best top-analyst consensus in the sector · Healthcare
About Phathom Pharmaceuticals
- CEO: Steven L. Basta
- Employees: 371
- 100 Campus Drive, Florham Park, NJ, 07932, US
- www.phathompharma.com
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Data from the stock’s TipRanks forecast page, read 123 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗